"If payers stick with the
current cost-sharing, I'd expect the shift to Part D-administered drugs could
lead to substantially higher patient cost sharing. However, this depends on the
Part D plan benefit design, as they can vary widely."
— Joe Paduda, founder and principal of Health Strategy
Associates, spoke with AIS's RADAR
on Drug Benefits about how the treatment of autoimmune disorders —
already costly — could shift amid the COVID-19 pandemic.
No comments:
Post a Comment